Prescription migraine drug recalled for manufacturing impurity above FDA limit
Glenmark Pharmaceuticals is recalling Rizatriptan Benzoate tablets for exceeding FDA acceptable limits of N-Nitroso Desmethyl Rizatriptan impurity. The recall affects 2,400 cartons distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for a manufacturing defect involving an impurity exceeding acceptable limits in a prescription medication. No illnesses or injuries have been reported in the source text, so the hazard remains theoretical. Per the rubric, theoretical hazards with no reported injury score at most 3.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Rizatriptan Benzoate Orally Disintegrating Tablets, 5mg (NDC 68462-467 and 68462-468), manufactured in India. The recall is due to manufacturing deviations where testing detected N-Nitroso Desmethyl Rizatriptan impurity at levels exceeding FDA acceptable limits.
The affected product was distributed nationwide in the United States. Two lot numbers are involved: Lot #19224857 (expiration 11/2024) and Lot #19232493 (expiration 6/2025). A total of 2,400 cartons were distributed.
Patients taking Rizatriptan Benzoate from the affected lots should contact their healthcare provider or pharmacy. Do not discontinue use of the medication without consulting a healthcare professional, as this could affect migraine treatment. Return the medication to a pharmacy or dispose of it according to local guidelines.
The recalled product
- Product
- RIZATRIPTAN BENZOATE (RIZATRIPTAN BENZOATE)
- Brand
- RIZATRIPTAN BENZOATE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- manufacturing-defect
- impurity
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot#: 19224857
- Exp. 11/2024 Lot#: 19232493
- Exp. 6/2025
UPCs (2)
- 0368462467060
- 0368462468067
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · RIZATRIPTAN BENZOATE
- HighRizatriptan benzoate tablets recalled for manufacturing defect with chemical impurity
FDA (Drugs) · 2025-07-23
- HighRizatriptan Benzoate tablets recalled for N-nitroso impurity above acceptable limits
FDA (Drugs) · 2025-07-23
- HighFDA Recalls Rizatriptan Benzoate Tablets for Manufacturing Impurity
FDA (Drugs) · 2024-06-12
- HighRizatriptan Benzoate Tablets Recalled for Excessive N-Nitroso Impurity
FDA (Drugs) · 2024-06-12
- HighPrescription Rizatriptan Benzoate Tablets Recalled for Chemical Impurity
FDA (Drugs) · 2024-06-12
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27